Inhibikase Therapeutics Initiates Development Of Second Generation c-Abl Inhibitors And Names IkT-148009 As Risvodetinib
Portfolio Pulse from Benzinga Newsdesk
Inhibikase Therapeutics has initiated the development of second-generation c-Abl inhibitors and has named IkT-148009 as Risvodetinib. The company plans to assess new molecules from internal discovery and other companies to enhance the suppression of neurodegeneration through c-Abl inhibition.
August 21, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inhibikase Therapeutics is developing second-generation c-Abl inhibitors, which could potentially enhance the company's product portfolio and future revenues.
The development of second-generation c-Abl inhibitors by Inhibikase Therapeutics could potentially enhance the company's product portfolio and future revenues. This is a positive development for the company and could potentially lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100